Research Outputs
Permanent URI for this communityhttps://hdl.handle.net/20.500.14288/2
Browse
50 results
Search Results
Publication Open Access #COVID19 and #Breastcancer: a qualitative analysis of tweets(Multidisciplinary Digital Publishing Institute (MDPI), 2022) Naganathan, G.; Cleland, J.; Reel, E.; Cil, T.; Bilgen, İdil; School of MedicineRapid and efficient communication regarding quickly evolving medical information was paramount for healthcare providers and patients throughout the COVID-19 pandemic. Over the last several years, social media platforms such as Twitter have emerged as important tools for health promotion, virtual learning among healthcare providers, and patient support. We conducted a qualitative thematic content analysis on tweets using the hashtags #BreastSurgery, #BreastCancer, #BreastOncology, #Pandemic, and #COVID19. Advocacy organizations were the most frequent authors of tweets captured in this dataset, and most tweets came from the United States of America (64%). Seventy-three codes were generated from the data, and, through iterative, inductive analysis, three major themes were developed: patient hesitancy and vulnerability, increased efforts in knowledge sharing, and evolving best practices. We found that Twitter was an effective way to share evolving best practices, education, and collective experiences among key stakeholders. As Twitter is increasingly used as a tool for health promotion and knowledge translation, a better understanding of how key stakeholders engage with healthcare-related topics on the platform can help optimize the use of this powerful tool.
Publication Metadata only A case of secondary hemophagocytic lymphohistiocytosis (HLH) following incomplete kawasaki's disease (KD). Importance of distinguishing recurrent kd from HLH(2014) Kebudi, R.; Dindar, A.; Gürakan, F.; Devecioğlu, O.; Sözmen, Banu Oflaz; Faculty Member; School of Medicine; 198711N/APublication Metadata only A population-based validation of the IGCCCG update consortium for survival in metastatic non-seminoma testis cancer(Oxford Univ Press, 2024) Incesu, Reha-Baris; Morra, Simone; Scheipner, Lukas; Barletta, Francesco; Baudo, Andrea; Garcia, Cristina Cano; Tappero, Stefano; Piccinelli, Mattia Luca; Tian, Zhe; Saad, Fred; Shariat, Shahrokh F.; de Cobelli, Ottavio; Terrone, Carlo; Chun, Felix K. H.; Carmignani, Luca; Briganti, Alberto; Ahyai, Sascha; Longo, Nicola; Tilki, Derya; Graefen, Markus; Karakiewicz, Pierre, I; Tilki, Derya; School of Medicine; Koç University HospitalBackground: In 2021, the International Germ Cell Cancer Collaborative Group (IGCCCG) Update Consortium reported improved overall survival (OS) rates in a modern cohort of metastatic non-seminoma testis cancer patients within each of the IGCCCG prognosis groups (96% in good vs. 89% in intermediate vs. 67% in poor), compared to the previous IGCCCG publication (92% in good vs. 80% in intermediate vs. 48% in poor). We hypothesized that a similar survival improvement may apply to a contemporary North-American population-based cohort of non-seminoma testis cancer patients. Patients and Methods: The Surveillance, Epidemiology, and End Results (SEER) database (2010-2018) was used. Kaplan-Meier plots and multivariable Cox regression models tested the effect of IGCCCG prognosis groups on overall mortality (OM). Results: Of 1672 surgically treated metastatic non-seminoma patients, 778 (47%) exhibited good vs. 251 (15%) intermediate vs. 643 (38%) poor prognosis. In the overall cohort, five-year OS rate was 94% for good prognosis vs. 87% for intermediate prognosis vs. 65% for poor prognosis. In multivariable Cox regression models predicting OM, intermediate (Hazard ratio [HR] 2.4, 95% confidence interval [CI] 1.4-3.9, P < 0.001) and poor prognosis group (HR 6.6, 95% CI 1.0-1.0, P < 0.001) were independent predictors of higher OM, relative to good prognosis group. Conclusions: The survival improvement reported by the IGCCCG Update Consortium is also operational in non-seminoma testis cancer patients within the most contemporary SEER database. This observation indicates that the survival improvement is not only applicable to centres of excellence, but also applies to other institutions at large.Publication Metadata only Adult philadelphia chromosome-positive acute lymphoblastic leukemia in daily practice: a multicenter experience(Elsevier, 2016) Tekgunduz, Emre; Goker, Hakan; Kaynar, Leylagul; Sari, Ismail; Pala, Cigdem; Dogu, Mehmet Hilmi; Turgut, Burhan; Korkmaz, Serdal; Tetik, Aysegul; Buyukasik, Yahya; Hacioglu, Sibel Kabukcu; Bozdag, Sinem Civriz; Ozdemir, Evren; Altuntas, Fevzi; N/A; Öztürk, Erman; Doctor; N/A; Koç University Hospital; N/AIn this retrospective, multicenter study, we evaluated the real-life outcomes of adult Philadelphia-positive acute lymphoblastic leukemia patients. The best results in terms of survival are achieved in patients who were treated with tyrosine kinase inhibitors during induction and received allogeneic hematopoietic cell transplantation as part of consolidation. Background: The prognosis of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) is generally poor. Currently, allogeneic hematopoietic cell transplantation (allo-HCT) is the only accepted therapy with curative potential. Patients and Methods: Herein, we report our multicenter, retrospective experience with 46 (23 female; 23 male) Ph+ ALL patients, who were treated off-study between 2005 and 2012. Results: The median age of the patients was 46 years (range, 19-73 years). During induction, 30 (65%), 13 (28%), and 3 (7%) patients received tyrosine kinase inhibitors (TKIs) concurrent with chemotherapy (TKIs/chemotherapy), chemotherapy only, and TKIs only, respectively. Following induction, rates of complete remission (CR) of the study population were 85% (n = 39). CR rate in patients receiving TKIs during induction (n = 33) was significantly higher compared with patients who received chemotherapy only (n = 13; P = .011). Taking TKIs during induction significantly reduced induction mortality (3.3% vs. 38%; P = .01). Allo-HCT was performed subsequently in 21 (46%) patients. More patients who received TKIs with or without chemotherapy (19/33; 58%) during induction were able to undergo to allo-HCT compared with patients who received chemotherapy only (2/13; 15%; P = .005). Median overall survival of patients who were treated with TKIs during induction and received allo-HCT (not reached; NR) was significantly prolonged compared with patients who received allo-HCT but without TKIs during induction (23.2 months) and to the rest of the cohort (21.2 months; P = .019). Conclusions: Current state-of-the art management of Ph+ ALL in real-life seems to be incorporation of TKIs to chemotherapy regimens and proceeding to allo-HCT, whenever possible.Publication Metadata only Antimicrobial treatment, agressive supportive treatment (intensive care unit-icu, extracorporeal membranous oxygenation -ecmo, granulocyte transfusions) may save life in septic shock in pediatric all(Wiley-Blackwell, 2015) Kebudi, R.; Bahar, M.; Hacı, I.; Ekinci, A.; Egeli, D.; Eren, O.; İnel, Y.; Paker, T.; Bayrak, Y.; Ergönül, O.; Dindar, A.; Sözmen, Banu Oflaz; Faculty Member; School of Medicine; 198711N/APublication Metadata only Azacitidine versus decitabine in patients with refractory anemia with excess blast-results of multicenter study(Elsevier, 2016) Salim, Ozan; Toptas, Tayfur; Avsar, Esin; Yucel, Orhan Kemal; Geduk, Ayfer; Mehtap, Ozgur; Tombak, Anil; Tiftik, Eyup Naci; Deveci, Burak; Kurtoglu, Erdal; Kara, Osman; Atagunduz, Isik Kaygusuz; Tuglular, Tulin Firatli; Undar, Levent; N/A; Öztürk, Erman; Ferhanoğlu, Ahmet Burhan; Doctor; Faculty Member; N/A; School of Medicine; Koç University Hospital, N/A; N/A; 18320The present study aimed to compare the efficacy and safety of azacitidine and decitabine in patients with myelodysplastic syndrome (MDS). A total of 88 patients diagnosed with refractory anemia with excess blast (RAEB) treated with azacitidine (n = 57) or decitabine (n = 31) were evaluated. Comparisons between azacitidine and decitabine groups were performed in the whole cohort, and in a 1:1 propensity score-matched cohort in order to reduce the simple selection bias. Patients who received azacitidine or decitabine had comparable overall response rates in both the unmatched (49.1% vs. 64.5%, p = 0.166) and the propensity-matched cohorts (52% vs. 68%, p = 0.248). The cumulative incidence of AML transformation at one year was comparable between azacitidine and decitabine in the unmatched (24.0% vs. 31.3%, p = 0.26) and in the propensity-matched cohorts (18.7% vs. 31.5%, p = 0.11). There was no difference in terms of transfusion requirement, febrile neutropenia episodes or the need for antifungal use during the treatment cycles in the propensity-matched cohort. The median overall survival was 20.4 months for azacitidine and 16.8 months for decitabine (p = 0.59). Finally, we found that at least a four-cycle treatment with any HMA was a favorable factor. In conclusion, both azacitidine and decitabine have similar efficacy and toxicity profiles in the treatment of MDS-RAEB.Publication Metadata only Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours-results from a Turkish multi-centre study(Oxford University Press, 2024) Olmez, Omer Fatih; Bilici, Ahmet; Er, Ozlem; Bisgin, Atil; Sevinc, Alper; Akman, Tulay; Uslu, Ruchan; Mandel, Nil Molinas; Yalcin, Suayib; Teomete, Mehmet; Gorumlu, Gurbuz; Demir, Atakan; Namal, Esat; Alici, Suleyman; Bavbek, Sevil; Paksoy, Fatma; Basaran, Gul; Ozer, Leyla; Sener, Nur; Harputluoglu, Hakan; Selçukbiricik, Fatih; School of MedicineObjective The objective of this multi-centre, real-world study was to examine the potential influence of comprehensive molecular profiling on the development of treatment decisions or adjustments for patients with advanced solid malignancies. We then evaluated the impact of these informed choices on patient treatment outcomes.Methods The study encompassed 234 adult patients (mean age: 52.7 +/- 14.3 years, 54.7% women) who were diagnosed with solid tumours at 21 different medical centres in Turkey. Remarkably, 67.9% of the patients exhibited metastasis at the time of diagnosis. We utilized an OncoDNA (Gosselies, Belgium) platform (OncoDEEP) integrating next-generation sequencing with additional tests to harvest complex molecular profiling data. The results were analyzed in relation with two specific outcomes: (i) the impact on therapeutic decisions, including formulation or modifications, and (ii) associated treatment response.Results Out of the 228 patients with final molecular profiling results, 118 (50.4%) had their treatment modified, whilst the remaining 110 (47.0%) did not. The response rates were comparable, with 3.9 versus 3.4% for complete response, 13.6 versus 29.3% for partial response, 66.9 versus 51.7% for progressive disease and 15.5 versus 15.5% for stable disease for treatments informed and not informed by complex molecular profiling, respectively (P = 0.16).Conclusion Our real-world findings highlight the significant impact of complex molecular profiling on the treatment decisions made by oncologists for a substantial portion of patients with advanced solid tumours. Regrettably, no significant advantage was detected in terms of treatment response or disease control rates. Our real-world study reveals complex molecular profiling significantly impacts treatment decisions for advanced solid tumour patients, though without significant differences in treatment responses.Publication Metadata only Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion(Elsevier, 2014) Eskazan, Ahmet Emre; Eyice, Deniz; Kurt, Enes Ali; Elverdi, Tugrul; Yalniz, Fevzi Firat; Salihoglu, Ayse; Ar, Muhlis Cem; Aydin, Seniz Ongoren; Baslar, Zafer; Aydin, Yildiz; Tuzuner, Nukhet; Ozbek, Ugur; Soysal, Teoman; N/A; Ferhanoğlu, Ahmet Burhan; Faculty Member; School of Medicine; 18320Dasatinib is a potent second generation TKI, and it is widely used in patients with CML, both in the up-front setting and failure after imatinib. Lymphocytosis in cases receiving dasatinib therapy has been shown to be associated with pleural effusion (PE) and better outcome. Although patients who gather lymphocytosis during dasatinib have superior responses, there is only little data about the correlation between PE, response rates, and survival. In order to answer this question, the aim of our study was to determine the frequency of PE and lymphocytosis among our CML patients receiving second-line dasatinib, and to compare the responses and outcomes between patients with or without PE. There were 18 patients (44%) who developed PE, in a total of 41 patients, with a median time of 15 months. Lymphocytosis was observed in nine patients (9/41, 22%) with a median duration of 6.5 months of dasatinib treatment. There were fourteen patients with at least one comorbidity that may play a role in the generation of PE. The cumulative MMR and CCyR rates were greater in PE+ patients (p < 0.05). The PFS was significantly higher in PE+ group than PE-patients (p = 0.013), also the OS was higher among PE+ patients than PE- group (p = 0.042). In patients with a grade I/II PE, and durable responses under dasatinib, performing the management strategies for the recovery of effusion, together with continuing dasatinib can be a reasonable choice mainly in countries where third generation TKIs are not available. But alternative treatment strategies such as nilotinib or third generation TKIs can be chosen in patients with grade III/IV PE especially if the quality of life is severely affected. (C) 2014 Elsevier Ltd. All rights reserved.Publication Metadata only Comorbidity in small cell lung cancer: prognostic impacts of hypertension/coronary artery disease, diabetes mellitus, and chronic obstructive pulmonary disease(Taylor & Francis Inc, 2024) Taş, Faruk; Öztürk, Akın; Ertürk, Kayhan; School of MedicineComorbidity, the most important components of which are hypertension/coronary artery disease (HTN/CAD), diabetes mellitus (DM), and chronic obstructive pulmonary disease (COPD), is frequently encountered in small cell lung cancer (SCLC) patients. We aimed to assess the possible impacts of these major comorbidities on the prognoses of SCLC patients. A total of 378 SCLC patients were analyzed retrospectively. We did not ascertain the effect of comorbidity on survival in SCLC patients in general;and similarly, the presence of HTN/CAD and COPD did not adversely affect the outcome. However, lower survival rates were observed in patients with SCLC coexisting with DM.Publication Open Access Could the long-term oncological safety of laparoscopic surgery in low-risk endometrial cancer also be valid for the high–intermediate-and high-risk patients? a multi-center Turkish gynecologic oncology group study conducted with 2745 endometrial cancer cases. (TRSGO-end-001)(Multidisciplinary Digital Publishing Institute (MDPI), 2021) Vardar, Mehmet Ali; Güzel, Ahmet Barış; Taşkın, Salih; Güngör, Mete; Özgül, Nejat; Salman, Coşkun; Küçükgöz-Güleç, Ümran; Khatib, Ghanim; Duender, Ilkkan; Ortaç, Fırat; Yüce, Kunter; Terek, Coşan; Şimşek, Tayup; Özsaran, AydIn; Onan, Anıl; Çoban, Gonca; Topuz, Samet; Demirkıran, Fuat; Takmaz, Özgüç; Köse, M. Faruk; Göçmen, Ahmet; Seydaoğlu, Gülşah; Gümürdülü, Derya; Ayhan, Ali; Taşkıran, Çağatay; Faculty Member; School of Medicine; Koç University Hospital; 134190This study was conducted to compare the long-term oncological outcomes of laparotomy and laparoscopic surgeries in endometrial cancer under the light of the 2016 ESMO-ESGO-ESTRO risk classification system, with particular focus on the high–intermediate-and high-risk categories. Using multicentric databases between January 2005 and January 2016, disease-free and overall survivals of 2745 endometrial cancer cases were compared according to the surgery route (laparotomy vs. laparoscopy). The high–intermediate-and high-risk patients were defined with respect to the 2016 ESMO-ESGO-ESTRO risk classification system, and they were analyzed with respect to differences in survival rates. Of the 2745 patients, 1743 (63.5%) were operated by laparotomy, and the remaining were operated with laparoscopy. The total numbers of high–intermediate- and high-risk endometrial cancer cases were 734 (45%) patients in the laparotomy group and 307 (30.7%) patients in the laparoscopy group. Disease-free and overall survivals were not statistically different when compared between laparoscopy and laparotomy groups in terms of low-, intermediate-, high–intermediateand high-risk endometrial cancer. In conclusion, regardless of the endometrial cancer risk category, long-term oncological outcomes of the laparoscopic approach were found to be comparable to those treated with laparotomy. Our results are encouraging to consider laparoscopic surgery for high–intermediate- and high-risk endometrial cancer cases.